Lipocine (LPCN) Stock Price, News & Analysis

Company Overview

Lipocine Inc. is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S. Food and Drug Administration for the treatment of male hypogonadism. In parallel, Lipocine is advancing LPCN 1144, an oral formulation of testosterone undecanoate, for the treatment of nonalcoholic steatohepatitis (NASH) and related metabolic disorders. Ongoing clinical studies seek to confirm the safety and efficacy of these candidates while exploring additional indications that may benefit from Lipocine’s delivery platforms.

Headquartered in Salt Lake City, Utah, Lipocine serves a global market, conducting operations and clinical trials primarily in the United States but also engaging with partners and regulators in Europe and Asia. The organization maintains research collaborations and licensing discussions to extend the reach of its technologies and to explore new therapeutic areas. Its facilities support formulation development, analytical testing, and scale-up processes needed to transition products from the laboratory to commercial manufacture.

Since its founding in 1996, Lipocine has been led by Chief Executive Officer William D. Kaan, who has guided the company through pivotal clinical milestones and regulatory submissions. Under his leadership, Lipocine continues to pursue a strategic path toward product approvals, commercialization partnerships, and the expansion of its lipid-based delivery platforms. The company’s management team comprises experienced professionals in pharmaceutical development, regulatory affairs, and corporate strategy, all dedicated to delivering innovative therapies that improve patient outcomes.

Key Stats

• Today's Range: $2.33 to $2.46
• 50-Day Range: $1.94 to $10.00
• 52-Week Range: $1.81 to $12.37
• Volume: 157,440 shs
• Average Volume: 443,329 shs
• Market Capitalization: $19.51 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $15.00
• Consensus Rating: Hold

Lipocine Stock Analysis - MarketRank™

Lipocine scored higher than 59% of companies evaluated by MarketBeat, and ranked 334th out of 857 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Hold

Consensus Rating

Lipocine has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 strong buy rating, no buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Lipocine has a consensus price target of $15.00, representing about 517.3% upside from its current price of $2.43.

Amount of Analyst Coverage

Lipocine has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Lipocine is -1.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Lipocine is -1.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Lipocine has a P/B Ratio of 0.93. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.25% of the float of Lipocine has been sold short.

Short Interest Ratio / Days to Cover

Lipocine has a short interest ratio ("days to cover") of 0.09, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lipocine has recently increased by 7.28%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lipocine does not currently pay a dividend.

Dividend Growth

Lipocine does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Lipocine this week, compared to 2 articles on an average week.

Search Interest

11 people have searched for LPCN on MarketBeat in the last 30 days. This is an increase of 57% compared to the previous 30 days.

Company Ownership

• Score: 3.9 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

2 insiders have purchased shares of Lipocine in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $434,600.00 in company stock, which represents 2.2272% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Lipocine insiders have bought more of their company's stock than they have sold. Specifically, they have bought $434,600.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

6.35% of the stock of Lipocine is held by insiders.

Percentage Held by Institutions

9.11% of the stock of Lipocine is held by institutions.

LPCN Stock Analysis - Frequently Asked Questions

How have LPCN shares performed this year?

Lipocine's stock was trading at $8.03 at the beginning of the year. Since then, LPCN shares have decreased by 69.7% and is now trading at $2.43.

How were Lipocine's earnings last quarter?

Lipocine Inc. (NASDAQ:LPCN) released its earnings results on Tuesday, March, 10th. The specialty pharmaceutical company reported ($0.34) earnings per share for the quarter, beating analysts' consensus estimates of ($0.60) by $0.26. The specialty pharmaceutical company earned $1.15 million during the quarter, compared to analyst estimates of $0.12 million. Lipocine had a negative trailing twelve-month return on equity of 59.30% and a negative net margin of 487.00%.

When did Lipocine's stock split?

Lipocine shares reverse split before market open on Friday, May 12th 2023.The 1-17 reverse split was announced on Friday, May 12th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

Who are Lipocine's major shareholders?

Lipocine's top institutional shareholders include AIGH Capital Management LLC (2.49%). Insiders that own company stock include John W Higuchi and Mahesh V Patel.
View institutional ownership trends.

How do I buy shares of Lipocine?

Shares of LPCN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Lipocine own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Lipocine investors own include Zomedica (ZOM), Plug Power (PLUG), Workhorse Group (WKHS), Ovid Therapeutics (OVID), FuelCell Energy (FCEL), Fortress Biotech (FBIO) and KALA BIO (KALA).

Company Calendar

• Last Earnings: 3/10/2026
• Today: 5/06/2026
• Next Earnings (Estimated): 5/07/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:LPCN
• CIK: 1535955
• Web: www.lipocine.com
• Phone: (801) 994-7383
• Fax: 801-994-7388
• Employees: 10
• Year Founded: 1997

Price Target and Rating

• Average Price Target for Lipocine: $15.00
• High Price Target: $15.00
• Low Price Target: $15.00
• Potential Upside/Downside: +517.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.69)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$9.63 million
• Net Margins: -487.00%
• Pretax Margin: -486.95%
• Return on Equity: -59.30%
• Return on Assets: -53.37%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.68
• Quick Ratio: 6.68

Sales & Book Value

• Annual Sales: $1.98 million
• Price / Sales: 9.86
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.61 per share
• Price / Book: 0.93

Miscellaneous

• Outstanding Shares: 8,030,000
• Free Float: 7,515,000
• Market Cap: $19.51 million
• Optionable: No Data
• Beta: 0.50